Colin
Board Sponsor
- Awards
- 2
Fursultiamine request:staple for stim users
This is present in the new version of AMP but I'd rather just buy it by itself as I do not want to use several of the other actives in AMP 2.0.
Please post in the the thread below (NutraPLanet subforum)to confirm interest and show demand for this in bulk form:
http://anabolicminds.com/forum/nutraplanet/84701-fursultiamine-request-staple.html
If you use stims (any sort of heart trouble is applicable) and/or have joint pain....read on.
The following is grifted from the AMP write up,which prompted a Pubmed search yielding the three studies posted below:
"Thiamine is one of the most important vitamins for carbohydrate and fat metabolism but it suffers from poor bioavailability. That is why easily absorbed thiamine pro-drugs were developed and fursultiamine is the most effective of them all. Cellular ATP production in muscles and the brain are greatly enhanced with fursultiamine, and it has been shown to improve exercise performance and reduce muscle fatigue. Fursultiamine is also known to reduce or eliminate the accelerated heartbeat that often accompanies the use of stimulants such as ephedrine."
The first study shows it has positive effect towards joint health and the latter two show evidence of cardiovascular benefit:
Review: 0
Click to change filter selection through MyNCBI.
1: Inflamm Res. 2005 Jun;54(6):249-55.Click here to read Links
Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis.
Kobayashi T, Notoya K, Nakamura A, Akimoto K.
Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka, 532-8686, Japan.
OBJECT AND DESIGN: The therapeutic effect of glucosamine hydrochloride (GH) and chondroitin sulfate (CS) in combination with fursultiamine, a vitamin B1 derivative, on the development of cartilage lesions was investigated in an animal model of osteoarthritis (OA). METHODS: The OA model was created by partial medial meniscectomy of the right knee joint (day 0). The rabbits were placed into three experimental groups: operated (OA) rabbits that received placebo treatment, OA rabbits that received GH (1000 mg/kg) + CS (800 mg/kg), and OA rabbits that received GH + CS + fursultiamine (100 mg/kg). Each treatment was initiated on day 3 and continued for 8 weeks. Macroscopic and histologic analyses were performed on the cartilage. The level of MMP-1 in OA cartilage chondrocytes was evaluated by immunohistochemistry. RESULTS: Only the group receiving combined treatment with GH + CS + fursultiamine showed a significant reduction in the severity of macroscopic and histologic lesions on tibial plateau, which is the weight bearing cartilage surface of the tibia, compared with placebo-treated OA rabbits. This treatment group also revealed a small, but significant, decrease in the body weight gain of the rabbits. In cartilage from placebo-treated OA rabbits, a significantly higher percentage of chondrocytes in superficial layer stained positive for MMP-1 compared with unoperated control. Rabbits treated with the GH + CS + fursultiamine revealed a significant reduction in the level of MMP-1. CONCLUSION: These results suggest that the chondroprotective effect of GH + CS is enhanced by the addition of fursultiamine in experimental OA. This effect was associated with a reduction in the level of MMP-1, which are known to play an important role in the pathophysiology of OA lesions.
PMID: 15973508 [PubMed - indexed for MEDLINE]
ll: 1 Review: 0
Click to change filter selection through MyNCBI.
1: Kokyu To Junkan. 1991 Jan;39(1):89-94.Links
[A case of beriberi heart--with special reference to the rapid effect of fursultiamine on hemodynamics]
[Article in Japanese]
Oimatsu H, Okada T, Sawai K, Satoh R, Mukai H, Kudoh C.
Department of Cardiology, Kushiro City General Hospital.
A 33-year-old man was admitted to Kushiro City General Hospital on February 27, 1989, because of palpitation, shortness of breath and anasarca. Eight months previously he had noted the onset of pretibial edema, which had progressed to anasarca. He had had a meal only once a day for nine months. Physical examination revealed a blood pressure of 114/46 mmHg and pulse rate of 80/min. The 3rd sound was audible. No rales in the chest and no hepatosplenomegaly were noted. Ascites, pretibial edema and anasarca were present. Vibration sensation was diminished, and the deep tendon reflexes were absent in the legs. The blood thiamine level on the 4th day of hospitalization decreased to 2.9 micrograms/dl. The red cell transketolase activity and TPP effect on the 10th hospital day were 0.76 IU/gHb and 11%, respectively. A chest roentogenogram showed pulmonary congestion and cardiomegaly (CTR 61.3%). The electrocardiogram showed non-specific T wave changes. On the echocardiogram, remarkable pericardial effusion and diffuse hypertrophy of the left ventricular wall were observed. In addition, the left ventricular wall motion showed a hyperkinetic state. On the basis of these findings, the diagnosis of beriberi heart was made. The hemodynamic study performed on the 10th hospital day showed a remarkable high cardiac output (CO) of 10.7 l/min and an extremely reduced total peripheral resistance (TPR) of 352 dynes.sec.cm-5. 15 min after intravenous administration of Fursultiamine 100 mg, CO decreased to 7.24 l/min and TPR increased to 848 dynes.sec.cm-5. Following the administration of Fursultiamine 75 mg, po/day, his symptoms and abnormal findings of clinical examination data rapidly improved.(ABSTRACT TRUNCATED AT 250 WORDS)
PMID: 2024080 [PubMed - indexed for MEDLINE]
1: Eur J Clin Nutr. 1992 Mar;46(3):227-34.Links
Beriberi cardiomyopathy.
Djoenaidi W, Notermans SL, Dunda G.
Department of Neurology, Airlangga University, Faculty of Medicine, Dr Soetomo Hospital, Surabaya, Indonesia.
In Indonesia beriberi is still endemic, but subclinical cases are not uncommon. Three patients suffering from beriberi presented with different clinical manifestations. One had the classical features of Shoshin beriberi and the other two had the non-alcoholic cardiac beriberi (chronic type). The cardiac symptoms of all three patients responded dramatically to thiamine tetrahydrofurfuryl disulfide; there was also some improvement of their polyneuropathy, consistent with the neurophysiologic findings and somatosensory evoked potentials (SSEPs). We conclude that SSEPs provide additional clinical information on beriberi polyneuropathy. The mortality of untreated cardiovascular beriberi is high. In view of the harmless nature of the treatment, a good case could be made for routine administration of thiamine to all patients in whom heart failure is present without clear evidence of the cause.
PMID: 1313764 [PubMed - indexed for MEDLINE]
This is present in the new version of AMP but I'd rather just buy it by itself as I do not want to use several of the other actives in AMP 2.0.
Please post in the the thread below (NutraPLanet subforum)to confirm interest and show demand for this in bulk form:
http://anabolicminds.com/forum/nutraplanet/84701-fursultiamine-request-staple.html
If you use stims (any sort of heart trouble is applicable) and/or have joint pain....read on.
The following is grifted from the AMP write up,which prompted a Pubmed search yielding the three studies posted below:
"Thiamine is one of the most important vitamins for carbohydrate and fat metabolism but it suffers from poor bioavailability. That is why easily absorbed thiamine pro-drugs were developed and fursultiamine is the most effective of them all. Cellular ATP production in muscles and the brain are greatly enhanced with fursultiamine, and it has been shown to improve exercise performance and reduce muscle fatigue. Fursultiamine is also known to reduce or eliminate the accelerated heartbeat that often accompanies the use of stimulants such as ephedrine."
The first study shows it has positive effect towards joint health and the latter two show evidence of cardiovascular benefit:
Review: 0
Click to change filter selection through MyNCBI.
1: Inflamm Res. 2005 Jun;54(6):249-55.Click here to read Links
Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis.
Kobayashi T, Notoya K, Nakamura A, Akimoto K.
Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka, 532-8686, Japan.
OBJECT AND DESIGN: The therapeutic effect of glucosamine hydrochloride (GH) and chondroitin sulfate (CS) in combination with fursultiamine, a vitamin B1 derivative, on the development of cartilage lesions was investigated in an animal model of osteoarthritis (OA). METHODS: The OA model was created by partial medial meniscectomy of the right knee joint (day 0). The rabbits were placed into three experimental groups: operated (OA) rabbits that received placebo treatment, OA rabbits that received GH (1000 mg/kg) + CS (800 mg/kg), and OA rabbits that received GH + CS + fursultiamine (100 mg/kg). Each treatment was initiated on day 3 and continued for 8 weeks. Macroscopic and histologic analyses were performed on the cartilage. The level of MMP-1 in OA cartilage chondrocytes was evaluated by immunohistochemistry. RESULTS: Only the group receiving combined treatment with GH + CS + fursultiamine showed a significant reduction in the severity of macroscopic and histologic lesions on tibial plateau, which is the weight bearing cartilage surface of the tibia, compared with placebo-treated OA rabbits. This treatment group also revealed a small, but significant, decrease in the body weight gain of the rabbits. In cartilage from placebo-treated OA rabbits, a significantly higher percentage of chondrocytes in superficial layer stained positive for MMP-1 compared with unoperated control. Rabbits treated with the GH + CS + fursultiamine revealed a significant reduction in the level of MMP-1. CONCLUSION: These results suggest that the chondroprotective effect of GH + CS is enhanced by the addition of fursultiamine in experimental OA. This effect was associated with a reduction in the level of MMP-1, which are known to play an important role in the pathophysiology of OA lesions.
PMID: 15973508 [PubMed - indexed for MEDLINE]
ll: 1 Review: 0
Click to change filter selection through MyNCBI.
1: Kokyu To Junkan. 1991 Jan;39(1):89-94.Links
[A case of beriberi heart--with special reference to the rapid effect of fursultiamine on hemodynamics]
[Article in Japanese]
Oimatsu H, Okada T, Sawai K, Satoh R, Mukai H, Kudoh C.
Department of Cardiology, Kushiro City General Hospital.
A 33-year-old man was admitted to Kushiro City General Hospital on February 27, 1989, because of palpitation, shortness of breath and anasarca. Eight months previously he had noted the onset of pretibial edema, which had progressed to anasarca. He had had a meal only once a day for nine months. Physical examination revealed a blood pressure of 114/46 mmHg and pulse rate of 80/min. The 3rd sound was audible. No rales in the chest and no hepatosplenomegaly were noted. Ascites, pretibial edema and anasarca were present. Vibration sensation was diminished, and the deep tendon reflexes were absent in the legs. The blood thiamine level on the 4th day of hospitalization decreased to 2.9 micrograms/dl. The red cell transketolase activity and TPP effect on the 10th hospital day were 0.76 IU/gHb and 11%, respectively. A chest roentogenogram showed pulmonary congestion and cardiomegaly (CTR 61.3%). The electrocardiogram showed non-specific T wave changes. On the echocardiogram, remarkable pericardial effusion and diffuse hypertrophy of the left ventricular wall were observed. In addition, the left ventricular wall motion showed a hyperkinetic state. On the basis of these findings, the diagnosis of beriberi heart was made. The hemodynamic study performed on the 10th hospital day showed a remarkable high cardiac output (CO) of 10.7 l/min and an extremely reduced total peripheral resistance (TPR) of 352 dynes.sec.cm-5. 15 min after intravenous administration of Fursultiamine 100 mg, CO decreased to 7.24 l/min and TPR increased to 848 dynes.sec.cm-5. Following the administration of Fursultiamine 75 mg, po/day, his symptoms and abnormal findings of clinical examination data rapidly improved.(ABSTRACT TRUNCATED AT 250 WORDS)
PMID: 2024080 [PubMed - indexed for MEDLINE]
1: Eur J Clin Nutr. 1992 Mar;46(3):227-34.Links
Beriberi cardiomyopathy.
Djoenaidi W, Notermans SL, Dunda G.
Department of Neurology, Airlangga University, Faculty of Medicine, Dr Soetomo Hospital, Surabaya, Indonesia.
In Indonesia beriberi is still endemic, but subclinical cases are not uncommon. Three patients suffering from beriberi presented with different clinical manifestations. One had the classical features of Shoshin beriberi and the other two had the non-alcoholic cardiac beriberi (chronic type). The cardiac symptoms of all three patients responded dramatically to thiamine tetrahydrofurfuryl disulfide; there was also some improvement of their polyneuropathy, consistent with the neurophysiologic findings and somatosensory evoked potentials (SSEPs). We conclude that SSEPs provide additional clinical information on beriberi polyneuropathy. The mortality of untreated cardiovascular beriberi is high. In view of the harmless nature of the treatment, a good case could be made for routine administration of thiamine to all patients in whom heart failure is present without clear evidence of the cause.
PMID: 1313764 [PubMed - indexed for MEDLINE]
